Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.05M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.05M.
Undervalued
The company’s latest PE is -15.79, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 100.94M shares, increasing 17.49% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 491.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.34.